

LISTING OF THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application.

1. (currently amended) A method of promoting neuronal fiber outgrowth or neuronal survival of cerebellar granule cells ~~treating or preventing nerve cell death or degeneration~~ comprising administering to a mammal in need of promoting neuronal fiber outgrowth or neuronal survival of cerebellar granule cells suffering from or susceptible to nerve cell death or degeneration a therapeutically effective amount of GDF-1 (SEQ ID NO:2) ~~or a fragment or derivative thereof~~, or a nucleic acid encoding GDF-1 ~~or a fragment or derivative thereof~~.

2. (original) A method of claim 1, wherein the ~~nerve cell death or degeneration is caused by~~ mammal has suffered brain or spinal cord trauma, brain or spinal cord ischemia, retinal ischemia, hypoxia or hypoglycemia.

3. (currently amended) A method of claim 1 or 2 wherein GDF-1 (SEQ ID NO:2) ~~or a fragment or derivative thereof~~, or a nucleic acid encoding GDF-1 ~~or a fragment or derivative thereof~~ is administered after the mammal has suffered nerve cell death or degeneration.

4. (currently amended) A method of claim 1 or 2 wherein GDF-1 (SEQ ID NO:2) ~~or a fragment or derivative thereof~~, or a nucleic acid encoding GDF-1 ~~or a fragment or derivative thereof~~ is administered to the mammal for at least about two weeks after the mammal has suffered nerve cell death or degeneration.

5-25 (cancelled).

26 (currently amended) A method of ~~any of~~ claims 1-25 wherein the GDF-1 ~~or a fragment or derivative thereof~~ is administered to the mammal.

27. (original) A method of claim 26, wherein the administered GDF-1 is encoded by SEQ ID NO:1.

28. (currently amended) A method of claim 26, wherein the administered GDF-1 ~~or a fragment or derivative thereof~~ is encoded by a nucleic acid that comprises a sequence that has at least about 70% sequence identity to SEQ ID NO:1.

29. (currently amended) A method of claim 26, wherein the administered GDF-1 ~~or a fragment or derivative thereof~~ is encoded by a nucleic acid that comprises a sequence that has at least about 80%, 90% or 95% sequence identity to SEQ ID NO:1.

30. (currently amended) A method of claim 26, wherein the administered GDF-1 ~~or a fragment or derivative thereof~~ is encoded by a sequence that hybridizes to SEQ ID NO:1 under normal stringency conditions.

31. (currently amended) A method of claim 26, wherein the administered GDF-1 ~~or a fragment or derivative thereof~~ is encoded by a sequence that hybridizes to SEQ ID NO:1 under high stringency conditions.

32. (currently amended) A method of claim 26, wherein the administered GDF-1 ~~or a fragment or derivative~~ has at least about 70% sequence identity to SEQ ID NO:2.

33. (currently amended) A method of claim 26, wherein the administered GDF-1 ~~or a fragment or derivative~~ has at least about 80%, 90% or 95% sequence identity to SEQ ID NO:2.

34. (original) A method of claim 26, wherein the administered GDF-1 has the sequence shown in SEQ ID NO:2.

Claims 35-40 (cancelled).

Claim 41 (currently amended) A method of ~~any of claims 1-40~~ wherein the administered GDF-1 ~~fragment or derivative~~, or the administered nucleic acid encodes a GDF-1 ~~fragment or derivative~~ exhibits at least about a 10% reduction in infarct volume in an *in vivo* cerebral ischemia assay.

Application No.: 09/756,481

5

Docket No.: 47506(47843)

Claims 42-82 (cancelled).